Salt Capital, a private equity investment firm focused on growth capital investments in the SADC region, and Proparco, the French Development finance institution, have acquired The Namibian Oncology Centre (NOC), a specialist cancer care provider in Namibia.
“By supporting The Namibian Oncology Centre, we are contributing to expanding access to...
Kurma Partners, a European healthcare venture capital firm and a Eurazeo group company, has announced the final closing of Biofund IV at €215m (US$252m), some 35% larger than its previous €160m Biofund III. It held the first close of Biofund IV in 2024 at €140m.
Total AUM across all Kurma Partners franchises now stand at €1bn.
In addition to Eurazeo, Biofund IV is backed by three cornerstone investors: CSL from Australia, the European Investment Fund (EIF), and Bpifrance. They are joined by other European institutional investors and family offices.
The new fund...